by Gene and Cell Therapies Targeting CNS Disorders Market is an emerging field that deals with the development of novel gene-based and cell-based therapies for the treatment of central nervous system (CNS) disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and epilepsy. These therapies aim to repair or replace damaged cells and genes in the brain to restore normal neuronal function and alleviate disease symptoms.
The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 1.2 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Therapeutic Advancements
One of the major trends driving the growth of the Gene and Cell Therapies Targeting CNS Disorders Market is the rising number of gene and cell therapy candidates in late-stage clinical trials for various CNS disorders. For instance, in September 2022, Passage Bio announced that it had dosed the first participant in its Phase 1/2 clinical trial of PBGM01, an AAV-delivered gene therapy candidate for GM2 gangliosidosis. Some other notable clinical-stage programs include Axovant’s AXO-Lenti-PD for Parkinson’s disease, Rocket Pharmaceutical’s RP-L401 for Canavan disease, and AveXis/Novartis’ gene therapy Zolgensma for spinal muscular atrophy. If successful, these programs have the potential to transform the treatment landscape of respective indications.
SWOT Analysis
Strength: Gene and cell therapies have potential to treat currently untreatable CNS disorders. These therapies aim to replace, repair or restore damaged cells by introducing new genes or cells into patient’s body.
Weakness: High costs associated with research and development of gene and cell therapies for CNS disorders. Long approval timelines due to complex validation and safety testing requirements.
Opportunity: Rising prevalence of Alzheimer’s, Parkinson’s, multiple sclerosis and other CNS disorders increasing demand for more effective treatment options. Growing interest from biotech companies and venture capital investments in this domain.
Threats: Complex nature of CNS disorders makes it difficult to prove efficacy and safety of gene and cell therapies. Slow patient enrollment for clinical trials also poses a challenge. Regulatory bottlenecks and uncertainties can delay market entry.
Key Takeaways
The Global Gene And Cell Therapies Targeting CNS Disorders Market is expected to witness high growth over the forecast period of 2023 to 2030. The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 1.2 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.
Regional analysis: North America holds the major share of the global market currently owing to favorable regulatory environment, high healthcare expenditure, and presence of key market players in the US and Canada conducting clinical trials and product launches. Europe is the second largest regional market driven by growing geriatric population and increasing prevalence of neurological disorders
Key players: Key players operating in the Gene and Cell Therapies Targeting CNS Disorders Market are Axovant Gene Therapies Ltd., ANTALIS PHARMA, Bristol-Myers Squibb, Astellas Pharma Inc., Mesoblast, AGTC. These players are focusing on new product development and approvals through clinical trials to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
